Annovis Bio Inc. announced on March 27, 2025, that it received a notice from the New York Stock Exchange (NYSE) on March 26, 2025. The notice stated that the company is no longer in compliance with NYSE continued listing standards, specifically Section 802.01B. This is due to its average global market capitalization falling below $50 million over a 30-trading-day period, while its stockholders’ equity was also less than $50 million.
As of March 25, 2025, the company's 30-trading-day average market capitalization was approximately $37.9 million, and its last reported stockholders’ equity as of December 31, 2024, was $9.3 million. The notice does not immediately affect business operations or SEC reporting obligations. However, the common stock trading symbol will have an added designation of ".BC" to indicate its below-criteria status.
Annovis has notified the NYSE that it will submit a plan within 45 days to regain compliance within 18 months. If the plan is not submitted or accepted, or if the company fails to comply, delisting proceedings will be initiated. This situation highlights significant financial challenges and risks for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.